The company collaborated to evaluate ficlatuzumab + cetuximab in the P-III registrational trial for patients with HPV- R/M HNSCC. The trial is expected to be initiated in H1’23
AVEO had entered into a similar deal with Merck KGaA to supply cetuximab outside of the US & Canada. In the recent agreement, Lilly will be responsible to provide cetuximab clinical drug supply in the same country while AVEO will serve as the study sponsor and will be responsible for trial execution
Ficlatuzumab + cetuximab showed a superior ORR including 2 patients with CR rate & m-PFS superior to historical data for current SoC. The combination therapy has the potential to be an imp. therapy option for HPV- R/M HNSCC, based on P-II trial results
Ref: Globenewswire | Image: Aveo Oncology
